Budesonide MMX is a low bioavailability corticosteroid oral once-daily formula-tion, which has a controlled rate of release throughout the colon, thanks to the multimatrix (MMX) formulation. It has been available for a decade in the USA and Europe for the induction of remission in patients with active, mild to moderate ulcerative colitis, particularly for those not responsive to mesalamine. The efficacy of budesonide MMX in this setting has been assessed by registrative randomized controlled trials showing a higher rate of clinical and endoscopic remission at 8 weeks compared with placebo, mostly in patients with proctosigmoiditis and left-side colitis. Since it is available in our therapeutic armamentarium, a few studies have confirmed the effectiveness of budesonide MMX also in real-life, high-lighting the high rate of clinical response and remission and the high safety profile. In the present review, we summarise clinical trials and real-life results of budesonide MMX, assessing its use and predictors of response and non-response in real-life.

Budesonide MMX in the treatment of ulcerative colitis: Current perspectives on efficacy and safety / G. Maconi, D. Camatta, R. Cannatelli, F. Ferretti, A. Carvalhas Gabrielli, S. Ardizzone. - In: THERAPEUTICS AND CLINICAL RISK MANAGEMENT. - ISSN 1176-6336. - 17(2021), pp. 285-292. [10.2147/TCRM.S263835]

Budesonide MMX in the treatment of ulcerative colitis: Current perspectives on efficacy and safety

G. Maconi
;
D. Camatta;A. Carvalhas Gabrielli;S. Ardizzone
2021

Abstract

Budesonide MMX is a low bioavailability corticosteroid oral once-daily formula-tion, which has a controlled rate of release throughout the colon, thanks to the multimatrix (MMX) formulation. It has been available for a decade in the USA and Europe for the induction of remission in patients with active, mild to moderate ulcerative colitis, particularly for those not responsive to mesalamine. The efficacy of budesonide MMX in this setting has been assessed by registrative randomized controlled trials showing a higher rate of clinical and endoscopic remission at 8 weeks compared with placebo, mostly in patients with proctosigmoiditis and left-side colitis. Since it is available in our therapeutic armamentarium, a few studies have confirmed the effectiveness of budesonide MMX also in real-life, high-lighting the high rate of clinical response and remission and the high safety profile. In the present review, we summarise clinical trials and real-life results of budesonide MMX, assessing its use and predictors of response and non-response in real-life.
Budesonide MMX; Effectiveness; Efficacy; Safety; Ulcerative colitis
Settore MED/12 - Gastroenterologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
Maconi et al. Ther Clin Risk Manag 2021.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 269.44 kB
Formato Adobe PDF
269.44 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/860037
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 1
social impact